Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Daniel R. Quast, Nina Schenker, Björn A. Menge, Michael A. Nauck, Christoph Kapitza, Juris J. Meier

Open source

DOI
10.2337/dc20-0720
Published
2020-07-09
Container
Diabetes Care
Publisher
American Diabetes Association
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2337/dc20-0720,
  title = {Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes},
  author = {Daniel R. Quast and Nina Schenker and Björn A. Menge and Michael A. Nauck and Christoph Kapitza and Juris J. Meier},
  year = {2020},
  journal = {Diabetes Care},
  doi = {10.2337/dc20-0720},
  url = {https://doi.org/10.2337/dc20-0720}
}

RIS

TY  - JOUR
TI  - Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
AU  - Daniel R. Quast
AU  - Nina Schenker
AU  - Björn A. Menge
AU  - Michael A. Nauck
AU  - Christoph Kapitza
AU  - Juris J. Meier
PY  - 2020
JO  - Diabetes Care
DO  - 10.2337/dc20-0720
UR  - https://doi.org/10.2337/dc20-0720
ER  - 

APA

Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020). Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc20-0720

Source records